Rice Bran Oil Cholesterol Randomized Trial: What the Evidence Says

Quick Answer

Rice Bran Oil Cholesterol Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• More broadly, cereal by-products from wheat, barley, oats, maize, and rice are increasingly recognized as important reservoirs of phytochemicals, including phenolic acids, flavonoids, carotenoids, alkylresorcinols, sterols, and dietary fiber-associated antioxidants, although their abundance and distribution vary according to grain type, anatomical fraction, genotype, pigmentation, and processing history. [Haghighat Khajavi Shabnam (2026); evidence level 3]
• These findings highlight both the technological potential of improved CP reactor designs and their applicability in stabilizing rice-based matrices while retaining nutritional functionality (Table ). [Haghighat Khajavi Shabnam (2026); evidence level 3]
• Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease globally, affecting approximately 38% of all adults worldwide. [Tan Verena M. H. (2026); evidence level 4]
• MASLD is defined as the presence of hepatic steatosis with at least one cardiometabolic risk factor, such as type 2 diabetes, obesity, or dyslipidemia, in the absence of significant alcohol consumption. [Tan Verena M. H. (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For rice bran oil cholesterol randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Haghighat Khajavi Shabnam (2026). Valorization of Rice By‐Products Through Conventional and Emerging Extraction Technologies: Trends, Challenges, and Applications. DOI: 10.1111/1541-4337.70511. PMCID: PMC13184422. PMID: 42152590. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13184422/
• Tan Verena M. H. (2026). Development of the Asian Mediterranean Diet and its sensory acceptability in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). DOI: 10.1186/s40795-026-01318-z. PMCID: PMC13195862. PMID: 41975554. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13195862/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.